🏆 The winning study ofthe
#BialAwardinBiomedicine 2025, publishedin
@ScienceMagazine in 2018, “Gut microbiome influences efficacy ofPD-1–based immunotherapy against epithelial tumors,” documents one ofthe mostsignificant recent advances in the treatment of several types of cancer, as it establishesthat the gut microbiome- the collection of bacteria residingin the human intestine - plays a decisiverole in the effectiveness of immunotherapy.
🙌 Congratulations to all 48 international researchers involvedin this award‑winning study. Takingthe stageare the lead authors, Laurence Zitvogel and Guido Kromer , internationally renowned French academics, accompanied by the first authorsBertrand Routy, Emmanuelle Le Chatelier and
@derosa_lisa.
🎓
@GustaveRoussy,
@UnivParisSaclay, Université Paris Cité, Assistance Publique - Hôpitaux de Paris, Aix-Marseille University,
@Inserm,
@laliguecancer,
@MgpsLab, EverImmune,
@HParisStJoseph, Rennes Private Hospitals – Saint-Grégoire (Vivalto Santé),
@CGFL_Dijon, Artimmune/INEM,
@hopitalbichat (FR); Hospital Clinic of Barcelona, University of Barcelona,
@CarrerasIJC (ES); University Hospital Heidelberg,
@DKFZ,
@TU_Muenchen, Ludwig Maximilians University (GE),
@AstraZeneca (UK),
@LeicaBio (US); University of Montreal Hospital Research Centre (CRCHUM),
@UCalgary (CA),
@CSL (AU), e Changchun GeneScience Pharmaceutical Co (CN).
#BialFoundation #Biomedicine #Cancer #Immunology